2 The technologies
2.1 Two integrated sensor‑augmented pump therapy systems were identified during scoping as relevant to the assessment (see section 4 for additional details).
2.2 The integrated sensor‑augmented pump therapy systems, which combine continuous glucose monitoring with continuous subcutaneous insulin infusion, are intended to help people with type 1 diabetes manage their blood glucose levels. The systems are designed to continuously measure interstitial glucose levels (every few minutes) and allow immediate real‑time adjustment of insulin therapy. The systems produce alerts if the glucose levels become too high or too low. The MiniMed Paradigm Veo system can also automatically suspend insulin delivery if there is no response to a low‑glucose warning.